TABLE 1.

Demographic and clinical features of enrolled patients

Feature	Value
Gender, males/females	10/6 (62.5%/37.5%)
Age, years	69.0 ± 9.4 (57–80)
Age at onset of disease, years	52.8 ± 8.9 (36–63)
Disease duration, years	15.9 ± 6.6 (8–28)
LCIG duration, years	2.2 ± 2.1 (1–8)
Clinical phenotype, n (%)
PIGD	8 (50%)
Tremor dominant	2 (12.5%)
Indeterminate	6 (37.5%)
LEDD, mg	1317.9 ± 296.2 (885.3–1992.8)
LCIG infusion
Morning dose, ml	7.6 ± 2.6 (0–11)
Continuous dose, ml/h	2.8 ± 0.9 (1.6–4.6)
Total daily dose, ml	49.1 ± 14.6 (29.6–80)
MMSE	25.4 ± 3.1 (19–30)
MoCA	21.4 ± 4.1 (15–28)
New Freezing of Gait Questionnaire	18.6 ± 5.9 (10–31)
Falls Efficacy Scale	32.6 ± 18.4 (10–73)
MDS‐UPDRS I score	10.5 ± 5.0 (0–20)
MDS‐UPDRS II score	17.3 ± 5.0 (10–30)
MDS‐UPDRS IV score	8.5 ± 2.9 (3–12)
MDS‐UPDRS Item 4.1	2.1 ± 1.4 (0–4)
MDS‐UPDRS Item 4.2	1.3 ± 0.8 (0–2)
MDS‐UPDRS Item 4.3	1.5 ± 0.6 (1–3)
MDS‐UPDRS Item 4.4	1.5 ± 0.8 (0–3)
UDysRS I total score	13.6 ± 8.4 (0–25)
UDysRS II total score	5.3 ± 3.0 (0–9)

Note: Results are reported as average ± SD (range) or absolute values (percentage), as appropriate.

Abbreviations: LCIG, levodopa/carbidopa intestinal gel; LEDD, levodopa equivalent daily dose; MDS‐UPDRS, Movement Disorder Society–Unified Parkinson's Disease Rating Scale; MMSE, Mini‐Mental State Examination; MoCA, Montreal Cognitive Assessment; PIGD, postural instability/gait difficulty; UDysRS, Unified Dyskinesia Rating Scale.